Clinical characteristics of patients
| Features . | No. of patients (%) . |
|---|---|
| Age | |
| Median | 59 y |
| Range | 21-92 y |
| Sex | |
| Male | 68 (38) |
| Female | 112 (62) |
| Performance status | |
| ECOG score 0-1 | 173 (96) |
| ECOG score 2-4 | 6 (3) |
| Unknown | 1 (1) |
| Ann Arbor Stage | |
| I | 115 (64) |
| II | 16 (9) |
| IV | 49 (27) |
| B symptoms | |
| Absent | 175 (97) |
| Present | 5 (3) |
| Serum LDH level | |
| Normal | 110 (61) |
| Elevated | 37 (21) |
| Unknown | 33 (18) |
| Serum β2-microglobulin level | |
| Normal | 43 (24) |
| Elevated | 23 (13) |
| Unknown | 114 (63) |
| Number of extranodal sites | |
| 1 | 139 (77) |
| More than 1 | 41 (23) |
| Nodal involvement | |
| Absent | 142 (79) |
| Present | 38 (21) |
| Percentage of blasts | |
| Less than 10% | 161 (89) |
| 10%-20% | 19 (11) |
| Bone marrow involvement | |
| Absent | 155 (86) |
| Present | 25 (14) |
| Autoimmune background | |
| Absent | 159 (88) |
| Present | 21 (12) |
| IPI | |
| Low to low-intermediate risk | 146 (81) |
| Intermediate/high to high risk | 31 (17) |
| Unknown | 3 (2) |
| Features . | No. of patients (%) . |
|---|---|
| Age | |
| Median | 59 y |
| Range | 21-92 y |
| Sex | |
| Male | 68 (38) |
| Female | 112 (62) |
| Performance status | |
| ECOG score 0-1 | 173 (96) |
| ECOG score 2-4 | 6 (3) |
| Unknown | 1 (1) |
| Ann Arbor Stage | |
| I | 115 (64) |
| II | 16 (9) |
| IV | 49 (27) |
| B symptoms | |
| Absent | 175 (97) |
| Present | 5 (3) |
| Serum LDH level | |
| Normal | 110 (61) |
| Elevated | 37 (21) |
| Unknown | 33 (18) |
| Serum β2-microglobulin level | |
| Normal | 43 (24) |
| Elevated | 23 (13) |
| Unknown | 114 (63) |
| Number of extranodal sites | |
| 1 | 139 (77) |
| More than 1 | 41 (23) |
| Nodal involvement | |
| Absent | 142 (79) |
| Present | 38 (21) |
| Percentage of blasts | |
| Less than 10% | 161 (89) |
| 10%-20% | 19 (11) |
| Bone marrow involvement | |
| Absent | 155 (86) |
| Present | 25 (14) |
| Autoimmune background | |
| Absent | 159 (88) |
| Present | 21 (12) |
| IPI | |
| Low to low-intermediate risk | 146 (81) |
| Intermediate/high to high risk | 31 (17) |
| Unknown | 3 (2) |